



Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications

Guest Editor:

Dr. Amalia Ruiz

Institute of Cancer Therapeutics,
University of Bradford, Richmond
Rd, Bradford BD7 1DP, UK

Deadline for manuscript
submissions:
closed (20 August 2022)

Message from the Guest Editor

Dear Colleagues,

This Special Issue aims to highlight recent advances in the development of novel nanotherapeutics for combination therapy and theranostic applications in cancer treatment.

Original research articles and reviews are welcome for this Special Issue. Research areas may include (but are not limited to) the following:

- Synthesis and characterisation of novel nanomaterials for combination therapies and/or theranostic applications,
- Multifunctionalisation strategies to develop novel theranostic drug delivery systems,
- Nanoformulations coloaded with different therapeutic agents,
- Cell-based delivery systems for theranostic applications,
- Novel nanosystems combining traditional chemotherapy with photothermal, photodynamic, radiotherapy, and immunotherapy,
- Safety evaluation of novel nanotherapeutics for combination therapies.

I look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma